The evolution of selective estrogen receptor modulators in osteoporosis therapy

References

• Draper MW. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann NY Acad Sci 2003;997:373–7
   PubMed Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317–26
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999–4008
   PubMed Web of Science ®Google Scholar
• Ostlund H, Keller E, Hurd YL. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann NY Acad Sci 2003;1007:54–63
   PubMed Web of Science ®Google Scholar
• Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 2000;85:4835–40
   PubMed Web of Science ®Google Scholar
• Kusec V, Virdi AS, Prince R, Triffitt JT. Localization of estrogen receptor-alpha in human and rabbit skeletal tissues. J Clin Endocrinol Metab 1998;83:2421–8
   PubMed Web of Science ®Google Scholar
• Vidal O, Kindblom LG, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res 1999;14:923–9
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Carlsson B, Grandien K, . Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863–70
   PubMed Web of Science ®Google Scholar
• Hackshaw A, Roughton M, Forsyth S, . Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011;29:1657–63
   PubMed Web of Science ®Google Scholar
• Hall JM, McDonnell DP. Selective estrogen receptor modulators: from bench, to bedside, and back again. Menopausal Med 2008;16:S1–6
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL, . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88
   PubMed Web of Science ®Google Scholar
• Freedman AN, Yu B, Gail MH, . Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29:2327–33
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78–84
   PubMed Web of Science ®Google Scholar
• Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 2008;26:5227–32
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG committee opinion: Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 2001;73:77–9
   PubMedGoogle Scholar
• EVISTA (raloxifene hydrochloride) tablet for oral use [package insert]. Indianapolis, IN: Eli Lilly and Company, 2008
   Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR). EVISTA. EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000184/WC500031005.pdf [serial online]; Accessed July 29, 2011
   Google Scholar
• Grady D, Cauley JA, Stock JL, . Effect of raloxifene on all-cause mortality. Am J Med 2010;123:469–7
   PubMed Web of Science ®Google Scholar
• FABLYN (lasofoxifene) tablet for oral use [package insert]. Kent, UK: Pfizer, Limited, 2009
   Google Scholar
• Pfizer. CONBRIZA 20 mg film-coated tablets Summary of Product Characteristics. 2011
   Google Scholar
• McDonnell DP. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res 2005;11:871–7s
   PubMed Web of Science ®Google Scholar
• Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene–conjugated estrogens combination. Mol Endocrinol 2009;23:75–85
   Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618–29
   PubMed Web of Science ®Google Scholar
• Taranta A, Brama M, Teti A, . The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30:368–76
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004;4:268–75
   PubMedGoogle Scholar
• Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001–5
   PubMed Web of Science ®Google Scholar
• Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905–12
   PubMed Web of Science ®Google Scholar
• Anzano MA, Peer CW, Smith JM, . Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123–5
   PubMed Web of Science ®Google Scholar
• Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996–2005
   PubMed Web of Science ®Google Scholar
• Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001;61:8683–8
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–91
   PubMed Web of Science ®Google Scholar
• Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 2011;49:376–86
   PubMed Web of Science ®Google Scholar
• Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 2008;287:40–6
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897–903
   PubMed Web of Science ®Google Scholar
• Lewis-Wambi JS, Kim HR, Curpan R, Grigg R, Sarker MA, Jordan VC. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and downregulates estrogen receptor α and cyclin D1. Mol Pharmacol 2011;80:610–20
   PubMed Web of Science ®Google Scholar
• Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118:117–24
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–97
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, . Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–61
   PubMed Web of Science ®Google Scholar
• Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441–52
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, . Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514–24
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Black DM, . Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293–300
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans GG, . Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522–32
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, . Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–37
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, . Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, . Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686–96
   PubMed Web of Science ®Google Scholar
• Ensrud K, LaCroix A, Thompson JR, . Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010;122:1716–24
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Neven P, Cummings S, . Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes. Menopause 2010;18:17–22
   Web of Science ®Google Scholar
• LaCroix AZ, Powles T, Osborne CK, . Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706–15
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, . Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–34
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049–54
   PubMed Web of Science ®Google Scholar
• McCloskey E, Johansson H, Oden A, Chines A, Kanis J. Assessment of the effect of bazedoxifene on non-vertebral fracture risk. J Bone Miner Res 24 (Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=  6c55b263–692e-4a37-b807-f7a153641564. Accessed October 18, 2010
   Google Scholar
• Christiansen C, Chesnut CH III, Adachi JD, . Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH, . Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109–15
   PubMed Web of Science ®Google Scholar
• Silverman SL, Chines AA, Kendler DL, . Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351–63
   PubMed Web of Science ®Google Scholar
• Palacios S, Silverman S, Levine AB, . Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study. Presented at the 13th International Menopause Society World Congress on Menopause; June 8–11, 2011; Rome, Italy. Climacteric 2011;14:59 (Abstr)
   Google Scholar
• de Villiers TJ, Chines AA, Palacios S, . Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567–76
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, . Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–38
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–24
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039–44
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25–54
   PubMed Web of Science ®Google Scholar
• Prolia™ (denosumab), injection, for subcutaneous use [package insert]. Thousand Oaks, CA: Amgen Inc., 2010
   Google Scholar
• Prolia (denosumab) solution for injection [package insert]. The Netherlands: Amgen Europe BV, 2010
   Google Scholar
• MacLean C, Newberry S, Maglione M, . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197–213
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133–52
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, . Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267–94
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–91
   PubMed Web of Science ®Google Scholar
• Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122: S33–45
   PubMed Web of Science ®Google Scholar
• Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755–63
   PubMed Web of Science ®Google Scholar
• Migliaccio S, Brama M, Spera G. The differential effects of bisphosphonates, SERMs (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2007;2:55–64
   PubMed Web of Science ®Google Scholar
• Eastell R, Reid DM, Vukicevic S, . The effects of lasofoxifene on bone turnover markers: the PEARL Trial. J Bone Miner Res 2008;23(Suppl 1):S81
   Google Scholar